Survey Based Report on Widely Prescribed Sitagliptin Drug for Treatment of Diabetes Mellitus

Sitagliptin is an effective and well-tolerated oral antidiabetic medication that enhances pancreatic islet cell sensitivity to glucose. Clinical studies involving over 22,000 patients confirm its ability to improve glycaemic control in type 2 diabetes (T2DM) with minimal risk of hypoglycaemia, weight gain, edema, or lipid abnormalities. It is weight- and lipid-neutral, making it a strong option for monotherapy or combination therapy. When combined with metformin, sitagliptin provides glycaemic benefits comparable to thiazolidinediones. It also improves β-cell function and may positively influence disease progression in individuals with impaired glucose tolerance